

Friday Satellite Symposia

Preceding the 64th ASH Annual Meeting and Exposition

M E D I C A L
CROSSFIRE[®]

How Do We Apply the Latest
Evidence on Novel Therapies to

Prevent and Treat GvHD?

IN-PERSON + LIVE STREAMING SATELLITE SYMPOSIUM

FRIDAY, DECEMBER 9, 2022

7:00 PM - 10:00 PM CT

PROGRAM CHAIR

Corey Cutler, MD, MPH, FRCPC

For more information, visit us at...

gotoper.com



STAY CONNECTED! Follow us @GoToPER and share your thoughts by using #GoToPER.

Dear Colleague:

On behalf of Physicians' Education Resource®, LLC (PER®), we would like to welcome you and thank you for choosing to attend Medical Crossfire®: How Do We Apply the Latest Evidence on Novel Therapies to Prevent and Treat GvHD?

Graft-vs-host disease (GvHD) remains a challenging complication of stem cell transplantation, but new inroads into biomarkers, prophylaxis, and targeted therapy have transformed management in recent years. In this live, hybrid educational symposium, experts in the management of GvHD provide a comprehensive overview of the state of the art across the treatment continuum. These presentations are supported by case presentations that illustrate the challenges and opportunities in GvHD management within the context of real-world practice.

In working together with PER®, we strive to make this activity, along with all PER® accredited continuing education (CE) activities, both useful and impactful for health care professionals like you who are involved with the care of patients with GvHD.

If there is anything additional that you need, if you experience an issue, or if you have an idea for a future activity that would help you in the care of your patients, please let us know.

We could not have our accredited CE activities without you, and we appreciate your commitment to learning about the latest advancements in the treatment of GvHD. Let's work together to make this an educational experience that will make a positive difference for our patients!

We hope you enjoy your experience at this first-class PER® symposium, and that you can attend another PER® accredited CE activity soon.

Regards,

Corey Cutler, MD, MPH, FRCPC

Associate Professor of Medicine
Harvard Medical School
Medical Director, Adult Stem Cell Transplantation Program
Dana-Farber Cancer Institute
Boston, MA

Jim Palatine, RPh, MBA

President
Physicians' Education Resource®, LLC
Pharmacy Times Continuing Education™
Cranbury, NJ
jpalatine@mjhllifesciences.com

AGENDA

7:00 PM	Welcome and Program Overview	Corey Cutler, MD, MPH, FRCPC
7:10 PM	Assessing the Clinical Impact of New Evidence on GvHD Prophylaxis	Sergio Giralt, MD, FACP, FASTCT
7:30 PM	Medical Crossfire® Interactive Case Discussion: A Patient Receiving a HSCT From an Unrelated Donor	Corey Cutler, MD, MPH, FRCPC
7:45 PM	Medical Crossfire® From the Floor: Interactive Question & Answer and Case Discussions from Learners	Corey Cutler, MD, MPH, FRCPC Sergio Giralt, MD, FACP, FASTCT Catherine Lee, MD Doris M. Ponce, MD
7:50 PM	What Will the Future Treatment Landscape Look Like for aGvHD?	Doris M. Ponce, MD
8:15 PM	Medical Crossfire® Interactive Case Discussion: Patient with aGvHD, refractory to steroids	Corey Cutler, MD, MPH, FRCPC Sergio Giralt, MD, FACP, FASTCT Catherine Lee, MD Doris M. Ponce, MD
8:35 PM	Medical Crossfire® From the Floor: Interactive Question & Answer and Case Discussions from Learners	Corey Cutler, MD, MPH, FRCPC Sergio Giralt, MD, FACP, FASTCT Catherine Lee, MD Doris M. Ponce, MD
8:40 PM	Novel Additions to the Therapeutic Landscape For the Management of Chronic GvHD (cGvHD)	Catherine Lee, MD
9:05 PM	Medical Crossfire® Interactive Case Discussion: Two Cases of Patients With Steroid-Refractory cGvHD	Corey Cutler, MD, MPH, FRCPC Sergio Giralt, MD, FACP, FASTCT Catherine Lee, MD Doris M. Ponce, MD
9:30 PM	Medical Crossfire® From the Floor: Interactive Question & Answer and Case Discussions From Learners	Corey Cutler, MD, MPH, FRCPC Sergio Giralt, MD, FACP, FASTCT Catherine Lee, MD Doris M. Ponce, MD
9:45 PM	Posttest and Discussion on Outcomes	Corey Cutler, MD, MPH, FRCPC
10:00 PM	Adjourn	Corey Cutler, MD, MPH, FRCPC

Target Audience

This educational activity is directed toward a global audience of medical oncologists, hematologic oncologists, hematologists, nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment of GvHD.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

- Explain the pathological mechanisms of acute and chronic GvHD underlying the rationale for therapeutic approaches to prevent and treat these posttransplant complications
- Evaluate the latest clinical evidence for therapeutic strategies investigated for the prevention and treatment of acute/chronic GvHD
- Apply strategies to promote the timely recognition and mitigation of treatment-related toxicities in patients at risk of developing GvHD or who are treated for GvHD
- Translate evidence-based approaches for the prophylaxis and treatment of acute and chronic GvHD into personalized treatment plans for patients after transplantation, to prevent or manage these post-transplant complications

Slides/e-Syllabus

Final slides will be uploaded to the e-syllabus on the PER® website by 12 PM EDT on Monday, December 12, 2022.

To access these materials, please visit <https://www.gotoper.com/gvhd1222iss-esyl>.

How to Request Credit

To complete the online evaluation and receive a certificate of credit or participation, please visit

<https://www.gotoper.com/gvhd1222iss-eval>.

The online evaluation and request for credit will be available immediately following the program and will remain available until January 23, 2023.

Accreditation/Designation of Credit

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 3.0 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 3.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Incyte Corporation; Janssen Biotech, Inc; Orca Bio; Pharmacyclics LLC, an AbbVie Company; Sanofi US and ST Shared Services, LLC, a Mallinckrodt Company.

Thank you for attending **Medical Crossfire®: How Do We Apply the Latest Evidence on Novel Therapies to Prevent and Treat GvHD?!**

To register for upcoming accredited CE live activities or to view our online accredited CE activities, please visit www.gotoper.com.

We appreciate your attendance and look forward to seeing you at future PER® accredited CE activities.

Faculty, Staff, and Planners' Disclosures

The following individuals have no relevant financial relationships with ineligible companies to disclose: the staff of Physicians' Education Resource®, LLC.

Faculty	Grant/Research Support	Consultant	Speakers' Bureau	Other
Corey Cutler, MD, MPH, FRCPC		Advisory Board/Consultant for: Mallinckrodt, Sanofi, CSL Behring, CTI BioPharma, Equillium, Bristol Myers Squibb, Janssen, Incyte, Deciphera Pharmaceuticals, Editas Medicine, Pfizer, CareDx, Omeros, Jazz Pharmaceuticals, Cimeio Therapeutics, Oxford Immune Algorithmics		Data and Safety Monitoring Board (DSMB): AlloVir, Da Volterra, BioLineRx, Pluristem Therapeutics, Angiocrine Biosciences
Sergio Giralt, MD, FACP, FASTCT	Miltenyi Biotec; Takeda Pharmaceutical Co; Celgene Corp; Amgen Inc; Sanofi; Johnson and Johnson, Inc; Actinium Pharmaceuticals, Inc			Advisory boards for: Kite Pharmaceuticals, Inc; Celgene Corp; Sanofi; Novartis; Johnson and Johnson, Inc; Amgen Inc; Takeda Pharmaceutical Co; Jazz Pharmaceuticals, Inc; Actinium Pharmaceuticals
Catherine Lee, MD	Incyte Corporation	Incyte Corporation, Kadmon Corporation, Kite Pharma, Bristol Myers Squibb, Fresenius Medical Care, Fresenius Kabi, CareDx	Kite Pharma	Incyte Corporation, study steering committee
Doris M. Ponce, MD	Incyte Corporation			

**Information accurate at time of printing*

PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing medical and/or nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

Physician Payments Sunshine Act

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.

Program Chair

**Corey Cutler, MD, MPH, FRCPC**

Associate Professor of Medicine
Harvard Medical School
Medical Director, Adult Stem Cell Transplantation Program
Dana-Farber Cancer Institute
Boston, MA

Faculty

**Sergio Giralt, MD, FACP, FASTCT**

Professor of Medicine
Weill Cornell Medical College
Melvin Berlin Family Chair in Myeloma Research
Deputy Head, Division of Hematologic Malignancies
Attending Physician, Adult BMT Service
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY

**Catherine Lee, MD**

Associate Professor of Medicine, Division of Hematology & Hematologic Malignancies
The University of Utah Transplant & Cellular Therapy Program at Huntsman Cancer Institute
Associate Professor of Medicine
Division of Hematology & Hematologic Malignancies
The University of Utah Transplant and Cellular Therapy Program at Huntsman Cancer Institute and Primary Children's Hospital
Salt Lake City, UT

**Doris M. Ponce, MD**

Associate Professor of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY


Notes

Did you miss one of our sessions?


Check out the On-Demand Video Updates
from the Annual Hematology Meeting

—*Rapid Archive from* → **NEW ORLEANS**


Archive will be available 24 hours after the live program ends.




**Optimized use of MRD in
Hematologic Malignancies**




**Maximizing Clinical Practice
for Hodgkin Lymphoma**




State-of-the-Art CMV Care




**State-of-the-Art Care for
MF and PV**




**Emerging Treatments for
Anemia in CKD**




**Exploring Gene Therapy in
Hemophilia B**



**Holistic Approaches in
Sickle Cell Disease Treatment**




**Diagnosing Uncommon
Hematologic Disorders**




**Diagnosis and Treatment of
Hemolytic Anemias**



**Novel Therapies to Prevent
and Treat GvHD**



**Optimized Treatments for
ALL in Adolescents and Adults**



**Novel Treatments for Indolent
and Aggressive B-Cell Lymphomas**



**Multidisciplinary Management
of BPDCN**



**Treating Transfusion-Related
Iron Overload**



Scan the QR code below
or visit gotoper.com/ash22
to view the symposia archive.

 **PER**[®]
Physicians'
Education
Resource, LLC
gotoper.com